Literature DB >> 25964856

Class II-associated invariant chain peptide as predictive immune marker in minimal residual disease in acute myeloid leukemia.

Marvin M van Luijn1, Willemijn van den Ancker2, S Marieke van Ham3, Arjan A van de Loosdrecht2.   

Abstract

The majority of patients with acute myeloid leukemia (AML) reach complete remission after high-dose chemotherapy. Still, half of these patients experience a relapse due to presence of minimal residual disease (MRD). Here we discuss the poor prognostic role of class II-associated invariant chain peptide (CLIP) expression on residual leukemic cells.

Entities:  

Keywords:  CD4+ T cells; HLA; immune escape; leukemia-associated phenotype; minimal residual disease

Year:  2015        PMID： 25964856      PMCID： PMC4353169          DOI： 10.4161/21624011.2014.941737

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Cancer despite immunosurveillance: immunoselection and immunosubversion.

Authors:  Laurence Zitvogel; Antoine Tesniere; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2006-09-15       Impact factor: 53.106

2.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 3.  Chemical biology of antigen presentation by MHC molecules.

Authors:  Sander I van Kasteren; Hermen Overkleeft; Huib Ovaa; Jacques Neefjes
Journal:  Curr Opin Immunol       Date:  2013-11-14       Impact factor: 7.486

4.  Absence of class II-associated invariant chain peptide on leukemic blasts of patients promotes activation of autologous leukemia-reactive CD4+ T cells.

Authors:  Marvin M van Luijn; Willemijn van den Ancker; Martine E D Chamuleau; Adri Zevenbergen; Theresia M Westers; Gert J Ossenkoppele; S Marieke van Ham; Arjan A van de Loosdrecht
Journal:  Cancer Res       Date:  2011-02-10       Impact factor: 12.701

5.  High INDO (indoleamine 2,3-dioxygenase) mRNA level in blasts of acute myeloid leukemic patients predicts poor clinical outcome.

Authors:  Martine E D Chamuleau; Arjan A van de Loosdrecht; Corine J Hess; Jeroen J W M Janssen; Adri Zevenbergen; Ruud Delwel; Peter J M Valk; Bob Löwenberg; Gert J Ossenkoppele
Journal:  Haematologica       Date:  2008-12       Impact factor: 9.941

6.  High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Authors:  Monique Terwijn; Wim L J van Putten; Angèle Kelder; Vincent H J van der Velden; Rik A Brooimans; Thomas Pabst; Johan Maertens; Nancy Boeckx; Georgine E de Greef; Peter J M Valk; Frank W M B Preijers; Peter C Huijgens; Angelika M Dräger; Urs Schanz; Mojca Jongen-Lavrecic; Bart J Biemond; Jakob R Passweg; Michel van Gelder; Pierre Wijermans; Carlos Graux; Mario Bargetzi; Marie-Cecile Legdeur; Jurgen Kuball; Okke de Weerdt; Yves Chalandon; Urs Hess; Leo F Verdonck; Jan W Gratama; Yvonne J M Oussoren; Willemijn J Scholten; Jennita Slomp; Alexander N Snel; Marie-Christiane Vekemans; Bob Löwenberg; Gert J Ossenkoppele; Gerrit J Schuurhuis
Journal:  J Clin Oncol       Date:  2013-09-23       Impact factor: 44.544

7.  High class II-associated invariant chain peptide expression on residual leukemic cells is associated with increased relapse risk in acute myeloid leukemia.

Authors:  Willemijn van den Ancker; Marvin M van Luijn; Martine E D Chamuleau; Angèle Kelder; Nicole Feller; Monique Terwijn; Adri Zevenbergen; Gerrit-Jan Schuurhuis; S Marieke van Ham; Theresia M Westers; Gert J Ossenkoppele; Arjan A van de Loosdrecht
Journal:  Leuk Res       Date:  2014-03-25       Impact factor: 3.156

Review 8.  From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer.

Authors:  Helen Angell; Jérôme Galon
Journal:  Curr Opin Immunol       Date:  2013-04-08       Impact factor: 7.486

9.  Immune evasion in acute myeloid leukemia: current concepts and future directions.

Authors:  Ryan M Teague; Justin Kline
Journal:  J Immunother Cancer       Date:  2013-08-27       Impact factor: 13.751

10.  Promiscuous binding of invariant chain-derived CLIP peptide to distinct HLA-I molecules revealed in leukemic cells.

Authors:  Marvin M van Luijn; Arjan A van de Loosdrecht; Margit H Lampen; Peter A van Veelen; Adri Zevenbergen; Michel G D Kester; Arnoud H de Ru; Gert J Ossenkoppele; Thorbald van Hall; S Marieke van Ham
Journal:  PLoS One       Date:  2012-04-26       Impact factor: 3.240
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.